| Document |
Document Title |
|
WO/2022/173961A1 |
Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a purified compound described herein.
|
|
WO/2022/174269A1 |
The present invention relates to a method of treating autoimmune/autoinflammatory diseases and hematological malignancies in a subject.
|
|
WO/2022/171185A1 |
The present invention provides a compound serving as an NLRP3 inhibitor. Specifically, the present invention provides a compound having a structure shown in the following formula (I), or an optical isomer, pharmaceutically acceptable sal...
|
|
WO/2022/170732A1 |
A truncated Evans blue modified fibroblast activation protein inhibitor compound, formed by linking truncated Evans blue, a fibroblast activation protein inhibitor, and a nuclide chelating group together by linking groups L1, L2, L3, L4,...
|
|
WO/2022/173022A1 |
The purpose of the present invention is to, in order to improve the light extraction efficiency of an organic EL element, provide a compound that has a low extinction coefficient and a high refractive index in a range of 450-750 nm in a ...
|
|
WO/2022/171811A1 |
The present invention relates to ligands of Fibroblast Activation Protein (FAP) for the active delivery of various payloads (e.g. cytotoxic drugs, radionuclides, fluorophores, proteins and immunomodulators) at the site of disease. In par...
|
|
WO/2022/173727A1 |
Provided herein are Sulfonamide compounds of Formula I: and pharmaceutically acceptable salts, tautomers, isotopologues, and stereoisomers thereof, wherein R1, R2, R, A, m, n, and p are as defined herein, compositions comprising an effec...
|
|
WO/2022/171123A1 |
Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparatio...
|
|
WO/2022/171653A1 |
Disclosed are TRPM8 modulators as defined by formula (I) for achieving a cooling effect on skin and mucousa.
|
|
WO/2022/169834A2 |
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules as defined within Formula I (as defined herein) which function as inhibitors of glucose-regulated protein 78 (G...
|
|
WO/2022/168808A1 |
The present invention pertains to: a compound that is represented by formula (I), that has a mPGES-1 inhibitory effect, and that is useful as an active ingredient of a medicine for treating and/or preventing diseases such as inflammation...
|
|
WO/2022/166890A1 |
Substituted pyridazine phenol derivatives and a preparation method therefor, specifically relating to a compound as shown in formula (VI) and a pharmaceutically acceptable salt thereof, which can be used as an NLRP3 inhibitor.
|
|
WO/2022/166747A1 |
The present invention relates to an amino lipid compound, namely a compound represented by chemical formula I, or a stereoisomer, tautomer, pharmaceutically acceptable salt or prodrug thereof. Moreover, also disclosed are a preparation m...
|
|
WO/2022/166468A1 |
A heterocyclic compound that acts as a BTK inhibitor, a preparation method therefor, and an application thereof in medicine. Specifically, the present invention relates to a compound represented by general formula (I) and a pharmaceutica...
|
|
WO/2022/166916A1 |
Provided are a substituted heteroaryl derivative, and a composition containing same and the use thereof, wherein the substituted heteroaryl derivative is a compound as represented by formula (I) or a tautomer, a stereoisomer, a prodrug, ...
|
|
WO/2022/166970A1 |
Provided in the present invention are a proteolysis targeting chimera, and a preparation method therefor and a pharmaceutical composition and the use thereof. Specifically, the proteolysis targeting chimera comprises the following struct...
|
|
WO/2022/166799A1 |
Provided are a fused tricyclic cyclin-dependent kinase inhibitor, and a preparation method therefor and a pharmaceutical use thereof. In particular, the structure of the fused tricyclic cyclin-dependent kinase inhibitor is shown in formu...
|
|
WO/2022/169998A1 |
Various amide compounds that bind Cbl-B, including those that are selective for C-Cbl, and methods of making and using the same. Representative amide compounds include molecules falling within the following formulae:
|
|
WO/2022/166844A1 |
Tricyclic compounds of formula (I), pharmaceutical compositions comprising same, methods for preparing same, and uses thereof, wherein each variable is as defined in the description.
|
|
WO/2022/170043A1 |
The invention provides compounds and pharmaceutical compositions thereof, which are useful for inhibiting EGFR, as well as methods for using such compounds to treat cancer associated with an EGFR or HER2 exon 20 insertion mutation.
|
|
WO/2022/167445A1 |
The present invention provides compounds of formula I, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/166917A1 |
A TYK2 inhibitor compound containing a bicyclic ring and the use thereof in the preparation of a drug for treating or preventing TYK2-related diseases.
|
|
WO/2022/166768A1 |
A tetrahydropyrrolocyclic compound as represented by formula (I), a pharmaceutically acceptable salt thereof, and an application thereof in preparation of a drug for treating a disease related to a selective orexin-2 (OX-2) receptor anta...
|
|
WO/2022/167866A1 |
The present disclosure relates in part to chemical modulators of protein phosphatase 2A (PP2A), comprising formula (I). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, aut...
|
|
WO/2022/167819A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof Formula (I) wherein R2, R3, R4, X1, X2, X3 and X4 are as defined in the specification, processes for t...
|
|
WO/2022/166469A1 |
A heterocyclic compound as a fibroblast growth factor receptor (FGFR) inhibitor, a preparation method therefor, and the pharmaceutical use thereof. In particular, the present invention relates to a compound represented by general formula...
|
|
WO/2022/170052A1 |
The present disclosure relates to compounds of Formula (I) or a stereoisomer, polymorph, hydrate, solvate, or pharmaceutically acceptable salt thereof. The present disclosure also relates to uses of the compounds, e.g., in treating or pr...
|
|
WO/2022/169997A1 |
Various lactam compound that binds Cbl-B, many of which are selective for Cbl-B over C-Cbl, and methods of making and using the same. Representative lactam compounds include molecules falling within the following formulae:
|
|
WO/2022/166638A1 |
A salt of a compound, as represented by formula I, a crystal form thereof, a pharmaceutical composition containing the salt and/or the crystal form thereof, and the use of the salt, the crystal form thereof and/or the pharmaceutical comp...
|
|
WO/2022/166570A1 |
A series of new-type dual-targeting degradation compounds, which have two independent inhibitor units and an E3 ligase ligand, or a pharmaceutically acceptable salt, hydrate, stereoisomer or prodrug thereof, a preparation method therefor...
|
|
WO/2022/169755A1 |
The present application discloses novel compounds of formula (I), pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a co...
|
|
WO/2022/169840A1 |
A combined cancer therapy comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, an immune checkpoint inhibitor, and optionally a radiotherapy.
|
|
WO/2022/169248A1 |
The present invention relates to a novel compound as a protein kinase inhibitor.
|
|
WO/2022/167682A1 |
The present invention relates to new compounds capable of inhibiting the activity of SHP2 phosphatase, having the general Formula (I).
|
|
WO/2022/167867A1 |
The present disclosure relates in part to chemical modulators of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, autoimmune disease, solid o...
|
|
WO/2022/166793A1 |
A compound serving as a selective CDK inhibitor, a pharmaceutical composition containing same, a useful intermediate for preparing the compound, and a use of the compound for preparing a drug for the treatment of cell proliferative disea...
|
|
WO/2022/166792A1 |
A salt, a solvate, a polymorph, a preparation method and the use of a benzazepine derivative. Specifically disclosed is a compound as shown in formula (I). The crystal form of the compound as shown in formula (I) has better solubility an...
|
|
WO/2022/167817A1 |
The invention relates to a process for preparing heterocyclic amide derivatives, to novel polymorphic forms obtained from said process and the use of said polymorphic forms for use in the treatment and prophylaxis of cancer.
|
|
WO/2022/166748A1 |
Provided in the present invention is a compound for treating or preventing vimentin-mediated diseases. The compound of the present invention is a s-triazine derivative, as shown in the following formula A, or a pharmaceutically acceptabl...
|
|
WO/2022/169696A1 |
Disclosed herein, inter alia, methods of synthesis of trans isomeric forms of G protein- coupled receptor modulators of high trans isomeric purity.
|
|
WO/2022/167631A1 |
The invention provides novel heteroaryl-substituted imidazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein A and R1 to R6 are as described herein. Further provided are pharmaceutical ...
|
|
WO/2022/167457A1 |
The present invention provides compounds of formula (I), compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/169184A1 |
The present invention relates to a novel compound and an organic light-emitting element comprising the novel compound in one or more organic layers to thus be highly efficient.
|
|
WO/2022/165114A1 |
The present invention relates to compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
|
|
WO/2022/164735A1 |
The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fi...
|
|
WO/2022/162447A1 |
The present invention generally relates to a process for preparation of chlorantraniliprole or a salt thereof. Further, the present invention relates to an improved process for preparation of intermediate of chlorantraniliprole.
|
|
WO/2022/165494A1 |
The present disclosure relates to free base and salt crystals of 2-(4-acetylbenzyl)-3-((4-fluorophenyl)amino)-5,7,7-trimethyl
-7,8-dihydro-2H-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)
-one, composition comprising the same and the meth...
|
|
WO/2022/164239A1 |
A novel pyrazole-carboxamide derivative compound provided as one example of the present invention exhibits an antagonist activity specific to cannabinoid receptor 1, and thus has a technical effect of effectively preventing or treating d...
|
|
WO/2022/160338A1 |
The present invention relates to a radioactively labeled ligand for a fibroblast activation protein-alpha imaging agent and a preparation method therefor, and belongs to the field of radiopharmaceutical chemistry. The radioactively label...
|
|
WO/2022/161274A1 |
Disclosed in the present invention are a pyrimidine-2,4-diamine compound, a preparation method therefor and the use thereof, relating to the technical field of pharmaceutical chemistry. The pyrimidine-2,4-diamine compound of the present ...
|
